Physician profile
Ivan Friedrich
NPI 1306890165
$5,719.98
in general payments reported to CMS, 2019-2025
32 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $128 · 2021: $902 · 2022: $1,175 · 2023: $462 · 2024: $711 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175 · Education: $46.68 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.14 |
| Education | $46.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.93 | 2019-2025 | |
| Janssen Biotech, INC. | $813.56 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $588.61 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $480.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $446.83 | 2021-2022 | |
| Celgene Corporation | $288.89 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $263.90 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $236.65 | 2025 | Tremfya |
| Gilead Sciences, INC. | $221.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $141.19 | 2019-2023 | Dificid, Zinplava |
| Olympus America INC. | $136.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $116.84 | 2019-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $107.42 | 2019-2022 | |
| Braintree Laboratories, INC. | $82.35 | 2019-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $76.71 | 2021-2024 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $67.53 | 2019-2022 | |
| Celltrion USA INC. | $65.15 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Lilly USA, LLC | $54.52 | 2024 | Omvoh |
| Allergan, INC. | $41.12 | 2019 | |
| Redhill Biopharma INC. | $39.43 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Novo Nordisk INC | $38.34 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $38.00 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $31.39 | 2025 | Zenpep, Vowst |
| Organon LLC | $29.97 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $28.66 | 2024-2025 | Voquezna |
| Ucb, INC. | $27.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.56 | 2022-2023 | Dupixent |
| Genzyme Corporation | $20.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.56 | 2024 | Bylvay |
| Evoke Pharma, INC. | $18.62 | 2023 | Gimoti |
| Endo Pharmaceuticals INC. | $12.94 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Friedrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.